Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA ...( - Oral presentation on the potent b...),Health

- Oral presentation on the potent blood glucose lowering effect of SGLT2

antisense inhibitors in multiple preclinical models - Eight additional presentations highlight significant activity in eight

new metabolic disease targets utilizing antisense

SAN FRANCISCO and CARLSBAD, Calif., June 10 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today the presentation of new preclinical data showing that antisense drugs potently reduce levels of sodium dependent glucose transporter type 2 (SGLT2), a key component in controlling glucose re-absorption in the kidney and the target of ISIS 388626. In addition, Isis presented results from eight research programs on novel targets that offer new mechanisms to treat metabolic diseases. The nine presentations (including two late-breaking abstracts) were presented during the American Diabetes Association's (ADA) 68th Scientific Sessions in San Francisco by Isis and its collaborators.

"These data provide further evidence of the power of Isis' antisense technology to discover and develop highly potent and specific molecules targeted against many novel targets to treat a broad spectrum of metabolic diseases," said Robert R. Henry, M.D., Professor of Medicine, University of California at San Diego, and Chief, Section of Diabetes, Endocrinology, and Metabolism at VA San Diego Healthcare System.

The presentation titled "Long Term Safety and Efficacy of ISIS 388626, an Optimized SGLT2 Antisense Inhibitor, in Multiple Diabetic and Euglycemic Species," showed that antisense reduction of SGLT2 produced the following results in preclinical models:

-- Lowered HbA1c, a measure of average blood glucose over time in

d
'/>"/>